GoPeptideGuide.com

This site is intended for research purposes only. Peptides are not recommended for human consumption.

Menu
Menu

IGF-1 LR3 (1mg)

Table of Contents

IGF-1 LR3 (1mg)

Quickstart Highlights

IGF-1 LR3 1mg dosage protocol involves daily subcutaneous injections to support research related to muscle growth, recovery, and nutrient partitioning.

  • Typically dosed from ~30mcg to 80mcg daily in a standard protocol
  • Advanced protocols may range up to 100mcg daily
  • Reconstitute to a practical concentration (up to 3mL) for accurate dosing
  • Store lyophilized in the freezer; reconstituted in the refrigerator
  • Frequent monitoring recommended; consult a qualified professional

Dosing & Reconstitution Guide

Educational guide for reconstitution and dosing protocol

Standard / Gradual Approach (3 mL = ~333 mcg/mL)

WEEK DAILY DOSAGE UNITS (mL) PER INJECTION
Weeks 1–2 ~33 mcg once daily 10 units
Weeks 3–4 50 mcg once daily 15 units
Weeks 5–6 66 mcg once daily 20 units
Weeks 7–8 80 mcg once daily 24 units

Ideal for most research protocols in the 30–80mcg daily range. Reconstitute with 3 mL of bacteriostatic water to achieve ~333 mcg/mL concentration.
Note: If dosing below 10 units (e.g., 20mcg → 6 units), consider smaller syringes for precise measurement.

  • Draw 3.0 mL of bacteriostatic water into a sterile syringe.
  • Inject the water slowly along the vial wall to reduce foam.
  • Gently swirl—avoid vigorous shaking.
  • Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.

Advanced / Aggressive Approach (2 mL = 500 mcg/mL)

WEEK DAILY DOSAGE Units (per injection)
Weeks 1–2 50 mcg once daily 10 units
Weeks 3–4 75 mcg once daily 15 units
Weeks 5–6 100 mcg once daily 20 units
Weeks 7–8 120 mcg once daily 24 units

Recommended for higher daily dosages (≥50mcg). Reconstitute with 2 mL of bacteriostatic water for a 500 mcg/mL solution.
Note: Protocols exceeding the total mg in a single vial will require additional vials.

  • Draw 2.0 mL of bacteriostatic water into a sterile syringe.
  • Slowly inject the water to minimize foam.
  • Gently roll/swirl the vial—no vigorous shaking.
  • Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.

Note: This guide is for educational purposes only. Always consult with a qualified healthcare professional.

Protocol Overview

A concise summary of daily administration for 8–12 weeks.

  • Goal : Support research on muscle growth, recovery, and performance
  • Schedule : Daily subcutaneous injections for 8–12 weeks
  • Dose Range : 30–80mcg daily (standard); up to ~100–120mcg (advanced)
  • Reconstitution : Up to 3mL for easy measuring
  • Storage : Keep lyophilized vials frozen; refrigerate after reconstitution

Dosing Protocol

Suggested once-daily injection approach, with options for gradual or advanced scaling.

  • Daily Dose : Start as low as 30–33mcg; increase as tolerated
  • Frequency : Once daily subcutaneous injection
  • Cycle Length : Typically 8–12 weeks
  • Maximum Dose: Advanced protocols may reach 120mcg daily
  • Timing : Same time each day is recommended for consistency

Storage Instructions

Proper storage ensures peptide integrity.

  • Lyophilized : Freeze at −20°C until mixing
  • Reconstituted : Refrigerate at 2–8°C
  • Use within 30 days of reconstitution
  • Avoid repeated freeze-thaw cycles

Suppilies Needed

Ensure you have these on hand for an 8–16 week cycle.

  • Peptide Vials :
    • 8 wks ≈ 3–4 vials (depending on dosage)
    • 12 wks ≈ 5–6 vials
    • 16 wks ≈ 7–8 vials
      • (Higher daily mcg requires more vials)
  • Insulin Syringes :
    • 1 syringe per day (8 wks ≈ 56 syringes, etc.)
  • Bacteriostatic Water : 1× 30ml
  • Alcohol Swabs: 1 box
IGF-1 LR3 (1mg)
View Supplier

Important Notes

Practical tips to enhance safety and efficacy.

  • Always use new, sterile insulin syringes & rotate injection sites.
  • Monitor blood glucose levels if necessary to avoid hypoglycemia.
  • Consult a professional if you observe any adverse reactions.
  • Track progress throughout the protocol, adjusting dosage as needed.

How This Works

IGF-1 LR3 is a modified insulin-like growth factor 1 with an extended half-life for potential anabolic and recovery benefits.

  • Extended Half-Life : Allows for once-daily administration
  • Tissue Growth & Repair : May support muscle, bone, and connective tissue recovery
  • Influences carbohydrate metabolism and protein synthesis pathways

Potential Benefits & Side Effects

Observed outcomes include enhanced recovery, but individual responses vary.

  • Supports muscle tissue development and protein synthesis
  • May assist in improved recovery time post-exercise
  • Possible side effects include hypoglycemia, joint pain, or injection-site redness
  • Rarely, excessive doses could lead to unwanted tissue growth

Lifestyle Factors

Complementary strategies for maximum benefit.

  • Pair with a nutrient-dense, protein-focused diet
  • Incorporate regular strength training and proper recovery methods
  • Maintain consistent sleep and stress-management practices

Injection Technique

Simple guidelines for safe daily injections.

  • Clean vial rubber stopper & injection site with alcohol swabs
  • Insert needle at a 45–90° angle into subcutaneous tissue
  • Inject slowly & rotate sites (abdomen, thigh, etc.)

Recommended Source

We recommend Go Alpha Labs for high-purity IGF-1 LR3.

Why Go Alpha Labs?​

  • Verifies ≥99% purity through independent lab testing
  • Trusted by researchers seeking reliable results
  • Follows rigorous manufacturing standards for consistent quality
Shop at Go Alpha Labs

Important Note:

This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.

References:

 

Source Link
Mayo Clinic – Mecasermin overview for subcutaneous route View Source
PMC – Research on IGF-1 functional roles View Source
USADA – IGF-1 doping and WADA prohibition View Source
FDA – Clinical data on IGF-1 for ALS View Source
Sigma-Aldrich – Guidance on reconstitution procedures View Source
PMC – Extended data on IGF-1 LR3 safety View Source
GenScript – LR3 IGF-1 receptor-grade documentation View Source
PubMed – Journal abstract on IGF-1 efficacy View Source
WebMD – Insulin-like growth factor-1 discussion View Source
R&D Systems – IGF-1 datasheet and lab protocols View Source
PubMed – Another study on IGF-1 usage View Source
Novus Biologicals – Recombinant IGF-1 product specification View Source
PMC – Analysis on IGF-1 clinical outcomes View Source
Scroll to Top